News and Updates
May 2024 Published Article from Hepatitis B Foundation: Dismantling Barriers to Hepatitis B and Delta Screening, Prevention, and Linkage to Care among the PWUD Community in Philadelphia
Advances in Viral Hepatitis B and D: Moving Toward the Goals of Elimination - A book from Dr. Robert Gish, leading expert in Hepatitis Delta, is available for purchase
November 2023 Blog Post: The Provider’s Perspective on Hepatitis Delta: A Conversation with Ilan Weisberg, MD
October 2023 Presentation: Hepatitis Delta: Increasing Awareness and Treatment Competencies For Practicing Clinicians
October 2023 Presentation: Disease Progression Among Commercially Insured Hepatitis Delta Virus Infected Patients in the United States
Current News
10/20/2024: Poor Hepatitis D Screening in HBV Patients Impacts Survival Outcomes
9/29/2024: Standardized Surveillance Case Definition for Hepatitis D Virus (HDV) Infection
9/29/2024: Availability of point-of-care HBV tests in resource-limited settings
7/22/2024: Pharmacists Boost Hepatitis D Treatment Success with Hands-On Education
7/1/2024: Drs Alan Bonder and Robert Gish Discuss Screening and Treatment for Hepatitis D
6/18/2024: Tobevibart, elebsiran can suppress hepatitis D virus: Phase 2 data
6/18/2024: Bulevirtide Plus Pegylated Interferon Can Maintain Undetectable Hepatitis D
6/18/2024: Video: Bulevirtide remains ‘efficacious, well tolerated’ in chronic hepatitis D at 2 years
6/18/2024: BJT-778 antibody therapy shows early promise in Hep D trial
6/12/2024: A changing landscape: Tracking and analysis of the international HDV epidemiology 1999–2020
3/8/2024: Growing Awareness: Limited Testing and Screening Bias for Hepatitis Delta Virus in Utah 2000–2021
2/14/2024: Eliminating viral hepatitis: no room for complacency
News Archive
11/29/2023: Transient elastography effectively detects severe fibrosis, cirrhosis in HDV
11/14/2023: Replicor updates REP 2139-Mg compassionate use and mechanistic data at AASLD 2023
11/9/2023: Hepatitis D: A Review
11/2023: Maternal-to-Child Transmission of Hepatitis B Virus and Hepatitis Delta Virus
11/2023: Hepatitis D: a neglected aspect of elimination efforts
10/03/2023: The elimination of hepatitis D as a public health problem: Needs and challenges
10/03/2023: AB-1659, A Potent Orally Bioavailable NTCP Inhibitor That Blocks Entry of HBV/HDV Viruses
10/02/2023: Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
09/12/2023: Late-Stage Trial in Chronic Hepatitis D Discontinued Due to Safety Concerns
08/12/2023: An Insight Into the Factors Affecting the Prevalence and Natural History of Hepatitis D
08/07/2023: A promising investigational therapeutic monoclonal antibody to treat chronic hepatitis B and D infections
07/28/2023: New Study Dismantles Everything We Knew About The Disease
07/26/2023: Diagnosis and Management of Hepatitis Delta Virus Infection
07/26/2023: Development of quantitative multiplex RT-qPCR one step assay for detection of hepatitis delta virus
07/06/2023: A Glimmer of Hope for an Orphan Disease
07/06/2023: Hepatitis D Virus Infection
07/06/2023: A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D
06/29/2023: Lonafarnib regimens ‘exceed end-of-treatment response’; oral therapy may be viable in HDV
06/23/2023: Gilead reports positive results in HDV patients previously unresponsive to therapy
06/23/2023: Gilead data reinforce case for Hepcludex in hepatitis delta
06/23/2023: EASL Clinical Practice Guidelines on hepatitis delta virus
06/22/2023: Advancing research, awareness, screening, and linkage to care to eliminate HDV in the U.S.
06/14/2023: Hepatitis Delta Virus Infection in the United States: If You Seek, You May Find
05/17/2023: The Many Functions Of The Hepatitis D Antigen Proteins
05/15/2023: With NICE nod, Gilead clears another regulatory hurdle in Europe for Hepcludex
05/10/2023: RNA Gymnastics: How Does Hepatitis Delta Virus Replicate?
05/05/2023: After FDA rejection, Gilead's Hepcludex looks set for full EU nod
04/07/2023: Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression
04/06/2023: Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection
03/17/2023: Hepatitis Delta, Aisf and Simit specialists present joint and updated document
03/14/2023: Scottish Medicines Consortium accepts treatment for chronic hepatitis delta virus
01/21/2023: Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy
01/11/2023: Identifying and Screening At-Risk Patients for Hepatitis Delta Virus: A Case Report
01/03/2023: A 3-Year Course Of Bulevirtide Monotherapy May Cure HDV Infection In Cirrhotics
11/26/2022: The Delta Delta: Gaps in screening and patient assessment for hepatitis D virus infection
11/11/2022: Bulevirtide Improves Health-Related Quality of Life (Phase 3 Clinical Trial Presentation at AASLD)
10/27/2022: COVID-19 Impacts HDV Screening, Patient Outcomes
09/2022: Presentation from International HBV Meeting: Combined results from the clinical trials MYR203 and MYR301, in patients with chronic hepatitis D
09/25/2022: Replicor Inc. has updated clinical data on the compassionate use program for treating chronic HBV/HDV co-infection in cirrhotic patients
09/2022: Diagnosing and Screening for Hepatitis D Viral Infection
08/30/2022: Hepatitis Delta virus in migrants: The challenge of elimination (ANRS CO22 HEPATHER cohort)
06/2022: EASL Presentation - Peginterferon Lambda combined with Lonafarnib diminished triphasic HDV kinetic pattern seen under PEG-IFN Lambda monotherapy
06/2022: EASL Presentation - Mathematical modeling of HDV RNA kinetics suggests high peginterferon lambda efficacy in blocking viral production
06/2022: EASL Presentation - Rising Clinical and Economic Burden Among Hepatitis D Patients Who Attended Spanish Hospitals
06/2022: EASL Presentation - Provider Factors Shaping Hepatitis Delta Screening
06/2022: EASL Presentation - Hepatitis delta virus reflex testing in patients with hepatitis B dramatically improves the HDV screening cascade: 10 years of real-world experience
06/27/2022: Vir Biotechnology Inc. (VIR) Announces New Clinical Data From its Broad Hepatitis B Program
06/16/2022: Review shines a light on the overlooked virus, hepatitis D
05/12/2022: Research Article Examining the Different Evolutionary Dynamics of the hepatitis B and hepatitis D virus
04/27/2022: Vir Biotechnology Unveils New Hepatitis D Clinical Program
03/23/2022: New Hepatitis D Central Resource Available from Healio
02/17/2022: Four Questions with Professor Maria Buti: Understanding Hepatitis D
02/11/2022: New Hepatitis Delta Podcast Episode: Viral Hepatitis: On the Road to Elimination
02/04/2022: Patient Perspective: Living with HBV and HDV Coinfection in Pandemic Times
01/20/2022: Hepatitis D Changing Context Global Prevalence
01/04/2022: New Slideset Updated on Don't Delay with Delta: Best Practices and Calls to Action in HDV
12/21/2021: Bulevirtide Improves Quality of Life in Chronic HDV
12/20/2021: Medical Minutes Podcasts on HDV Epidemiology and Universal Screening
12/16/2021: UN Adopts Resolution on Rare Diseases
12/13/2021: Bulevirtide Shows Real-World Efficacy Versus HDV
12/03/2021: Should We Screen All Patients with Hepatitis B for Hepatitis Delta?
12/01/2021: Hepatitis Delta Presentations from the 2021 AASLD Liver Meeting Now Available
11/19/2021: Gilead Files BLA for Bulevirtide to Treat Chronic HDV Infection
07/28/2021: Hepatitis D: Neglected Disease in the Race to Eliminate Viral Hepatitis by 2030
07/12/2021: Significant Disruptions in the International Incidence of Hepatitis Delta Virus
06/25/2021: Gilead Preps Filing for Hepatitis D Therapy Hepcludex in US
04/01/2021: Hepatitis Delta Infection Among Persons with HIV in Europe
10/7/2020: Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened?
9/17/2020: Hepcludex Launched in Germany, France, and Austria
8/5/2020: Hepcludex Approved by European Commission
2/18/2020: New Insights into Hepatitis B and Hepatitis Delta Virus Entry
1/2/2020: Hepatitis Delta Has Higher Health Care Cost Burden Than Hepatitis B
1/2020: The epidemiology of hepatitis delta virus infection in Cameroon
12/26/2019: REP2139 Demonstrates Functional Cure in Both HBV, HDV
11/12/2019: Eiger Announces Phase 2 LIFT Study Results During AASLD 2019
11/1/2019: MYR Pharmaceuticals to Present on Myrcludex B During AASLD 2019
11/1/2019: FDA Guidance to Help with Hepatitis Delta Drug Development
8/20/2019: Pegylated Interferon Lambda Receives FDA Breakthrough Therapy Designation
7/29/2019: Russia Plans Production of Myrcludex B
4/13/2019: MYR Announces Phase 2 Myrcludex B Trial Data at The International Liver Congress 2019
4/11/2019: Eiger Announces Phase 2 LIMT Hepatitis Delta Study Progress at The International Liver Congress 2019
12/18/2018: Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib
12/17/2018: Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib
6/4/2018: Digestive Disease Week: Hepatitis Delta: The 'Forgotten Virus' is Still Here
10/23/2018: MYR Pharma Announces FDA Breakthrough Therapy Designation for Myrcludex B
9/5/2017: Pegylated Interferon Lambda Receives FDA Orphan Drug Designation
7/27/2017: Pegylated Interferon Lambda Receives FDA Fast Track Designation
5/25/2017: MYR Pharma Announces Myrcludex B PRIME Designation by the EMA
12/22/2014: Lonafarnib Recieves Orphan Drug Designation by FDA and EMA